PL1718322T3 - Synergistyczne kompozycje z fk-228 - Google Patents

Synergistyczne kompozycje z fk-228

Info

Publication number
PL1718322T3
PL1718322T3 PL05719967T PL05719967T PL1718322T3 PL 1718322 T3 PL1718322 T3 PL 1718322T3 PL 05719967 T PL05719967 T PL 05719967T PL 05719967 T PL05719967 T PL 05719967T PL 1718322 T3 PL1718322 T3 PL 1718322T3
Authority
PL
Poland
Prior art keywords
antitumor agent
antitumor
synergistic compositions
agent
dna
Prior art date
Application number
PL05719967T
Other languages
English (en)
Inventor
Yoshinori Naoe
Takeshi Inoue
Yasuhiko Kano
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PL1718322T3 publication Critical patent/PL1718322T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PL05719967T 2004-02-25 2005-02-25 Synergistyczne kompozycje z fk-228 PL1718322T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004050520 2004-02-25
US56607704P 2004-04-29 2004-04-29
EP05719967A EP1718322B1 (en) 2004-02-25 2005-02-25 Synergistic compositions with fk-228
PCT/JP2005/003689 WO2005079827A2 (en) 2004-02-25 2005-02-25 Antitumor agent

Publications (1)

Publication Number Publication Date
PL1718322T3 true PL1718322T3 (pl) 2011-12-30

Family

ID=34889383

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05719967T PL1718322T3 (pl) 2004-02-25 2005-02-25 Synergistyczne kompozycje z fk-228

Country Status (11)

Country Link
US (2) US7951780B2 (pl)
EP (1) EP1718322B1 (pl)
JP (1) JP4930055B2 (pl)
AT (1) ATE516041T1 (pl)
CA (1) CA2557540A1 (pl)
CY (1) CY1111926T1 (pl)
DK (1) DK1718322T3 (pl)
PL (1) PL1718322T3 (pl)
PT (1) PT1718322E (pl)
SI (1) SI1718322T1 (pl)
WO (1) WO2005079827A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229521B1 (hu) * 2001-08-21 2014-01-28 Astellas Pharma Inc A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére
WO2003084611A1 (en) * 2002-04-05 2003-10-16 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
CN1777675A (zh) * 2003-02-19 2006-05-24 安斯泰来制药有限公司 预测组蛋白去乙酰化酶抑制剂抗肿瘤效果的方法
EP1670514B1 (en) * 2003-09-25 2010-06-23 Astellas Pharma Inc. Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20070197473A1 (en) * 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
US20100137239A1 (en) * 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
AU2007307080B2 (en) * 2006-10-06 2014-01-09 Bavarian Nordic A/S Methods for treating cancer with MVA
EP2815761A1 (en) * 2006-12-29 2014-12-24 Celgene Corporation Romidepsin-based treatments for cancer
US8691534B2 (en) * 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
WO2010036404A2 (en) * 2008-05-09 2010-04-01 University Of Maryland, Baltimore Novel retinamide retinoic acid metabolism blocking agents
EP2366398A1 (en) * 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with an HDAC inhibitor
NZ707377A (en) * 2010-06-07 2015-09-25 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
SG10201505475XA (en) 2010-07-12 2015-09-29 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN106860872B (zh) * 2017-01-18 2019-03-22 上海交通大学 用于逆转肿瘤对铂类抗癌药多药耐药性的两亲性药-药纳米颗粒药物及其制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH0315810A (ja) * 1989-06-13 1991-01-24 Minolta Camera Co Ltd カメラ
US6252058B1 (en) * 1997-11-05 2001-06-26 Timothy C. Thompson Sequences for targeting metastatic cells
JP2003513912A (ja) * 1999-11-10 2003-04-15 ワーナー−ランバート・カンパニー 組合せ化学療法
BR0016154A (pt) * 1999-12-08 2003-02-25 Xcyte Therapies Inc Depsipeptida e seus congêneres papa uso como imunossupressores
US7056884B2 (en) 2000-07-17 2006-06-06 Astellas Pharma Inc. Reduced FK228 and use thereof
US7396665B2 (en) 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
WO2002049501A2 (en) * 2000-12-18 2002-06-27 Board Of Regents, University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6620816B2 (en) * 2001-04-26 2003-09-16 Bristol-Myers Squibb Company Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
HU229521B1 (hu) 2001-08-21 2014-01-28 Astellas Pharma Inc A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére
CZ2004287A3 (cs) * 2001-08-31 2004-10-13 Bristol@Myersásquibbácompany Prostředky a způsoby pro léčení rakoviny
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
WO2003084611A1 (en) 2002-04-05 2003-10-16 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
AU2003226408B2 (en) 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
CN1777675A (zh) 2003-02-19 2006-05-24 安斯泰来制药有限公司 预测组蛋白去乙酰化酶抑制剂抗肿瘤效果的方法
DE602004027244D1 (de) 2003-06-27 2010-07-01 Astellas Pharma Inc Therapeutisches mittel für ein weichteilsarkom
CA2472842C (en) 2003-07-22 2012-05-29 Honda Motor Co., Ltd. Working machine
EP1670514B1 (en) 2003-09-25 2010-06-23 Astellas Pharma Inc. Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
US20050187148A1 (en) 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Also Published As

Publication number Publication date
US8822422B2 (en) 2014-09-02
JP4930055B2 (ja) 2012-05-09
DK1718322T3 (da) 2011-08-29
US20110160295A1 (en) 2011-06-30
CY1111926T1 (el) 2015-11-04
US20050187149A1 (en) 2005-08-25
CA2557540A1 (en) 2005-09-01
JP2007524650A (ja) 2007-08-30
WO2005079827A3 (en) 2005-12-08
US7951780B2 (en) 2011-05-31
EP1718322A2 (en) 2006-11-08
SI1718322T1 (sl) 2011-09-30
EP1718322B1 (en) 2011-07-13
ATE516041T1 (de) 2011-07-15
PT1718322E (pt) 2011-09-05
WO2005079827A2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
PT1718322E (pt) Composições sinérgicas com fk-228
WO2005063232A8 (en) Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
MXPA06003222A (es) Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
WO2009039460A3 (en) Co-administration of pimavanserin with other agents
WO2007030409A3 (en) In-can and dry coating antimicrobial compositions having hydroxy analogs of methionine and derivatives
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
EP2045251A4 (en) COMPOUNDS WHICH CAN INCLUDE THE UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
IL178727A0 (en) Tetrahydropyridothiophene derivatives and pharmaceutical compositions containing the same
WO2006061258A3 (en) Cytotoxic agents comprising new taxanes
MX2007014920A (es) Politerapia que comprende diarilureas para el tratamiento de enfermedades.
WO2007126832A3 (en) Pharmaceutical compositions for prevention of overdose or abuse
MX2008010801A (es) Indolopiridinas como moduladores de quinesina eg5.
TW200738283A (en) Formulations of conjugated estrogens and bazedoxifene
NO20073026L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
PL1591514T3 (pl) Zastosowanie dodatków do poprawy zapachu kompozycji węglowodorów oraz kompozycje węglowodorów zawierające takie dodatki
WO2007095258A3 (en) Rhamnolipid compositions and related methods of use
WO2006061259A3 (en) Cytotoxic agents comprising new c-2 modified taxanes
GB2437149B (en) Synergistic preservative systems and their use in cosmetic compositions.
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2007124382A3 (en) Inhaled imipenem
HK1112745A1 (en) Oligonucleotide and compositions comprising the same for treating b cell neoplasm
EP2357003A4 (en) ANTICANCER COMPOSITION COMPRISING ANTITUMOR SUBSTANCE AND AGENT AND HAVING INHIBITORY EFFECTS ON L1CAM ACTIVITY AND EXPRESSION